Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020473 (
hyperlipidemia
)
15,891
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Objective:
The study was aimed to evaluate the influences of erectile dysfunction (ED) in a rat model of stroke combined with
hyperlipidemia
(
HLP
).
Methods:
Male Sprague-Dawley rats were divided into control and
hyperlipidemia
(
HLP
) groups.
HLP
model was constructed by feeding with high-fat and cholesterol diets. Serum levels of total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL), triglyceride (TG), and non-HDL were identified to check the model was success. Stroke model was established by FeCl
3
. ICP/MAP value was detected to evaluate the erectile function of rats. Serum level of lipoproteins and the expressions of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF) were detected by ELISA. Hematoxylin-eosin (HE) staining of corpus cavernosum and measurement of penis length were utilized to assessment erectile function. Western blot was used.
Results:
TC, TG, LDL, and non-HDL-C in serum were up-regulated, while HDL level was attenuated. After treatment, the serum lipid level recovered. From the ICP/MAP values, the erectile function of both two treatment groups recovered. The expression of
PDE5A
was up-regulated, while the levels of eNOS and cGMP were suppressed after surgery. The length of penis was decreased, and corpus cavernosum was damaged following
HLP
and stroke. However, the erectile function was recovered after treatment.
Conclusion:
Stroke combined
HLP
caused ED through NO-cGMP-PDE5 pathway.
...
PMID:Research of stroke combined hyperlipidemia-induced erectile dysfunction in rat model. 3045 Oct 62
